|
DE2236930A1
(de)
|
1971-08-03 |
1973-02-15 |
Cameroun Etat |
Verfahren zur herstellung von desmosterol
|
|
GB1447456A
(en)
|
1973-06-20 |
1976-08-25 |
Teijin Ltd |
Process for preparing desmosterols
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
DE3823318A1
(de)
|
1988-07-09 |
1990-02-22 |
Bayer Ag |
(hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
|
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
MY108267A
(en)
|
1991-01-16 |
1996-09-30 |
Schering Corp |
Use of interleukin-10 in adoptive immunotherapy of cancer
|
|
TW263508B
(https=)
|
1991-02-12 |
1995-11-21 |
Pfizer |
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
JP3414433B2
(ja)
|
1993-03-01 |
2003-06-09 |
日本化薬株式会社 |
電子写真用トナー
|
|
DE19523446A1
(de)
|
1995-06-28 |
1997-01-02 |
Bayer Ag |
Benzotriazole
|
|
US6037367A
(en)
|
1995-07-14 |
2000-03-14 |
Smithkline Beecham Corporation |
Substituted-pent-4-ynoic acids
|
|
IL122944A
(en)
|
1995-08-10 |
2001-11-25 |
Bayer Ag |
Halogenobenzimidazoles, their preparation and microbicidal compositions containing them
|
|
AU722514B2
(en)
|
1995-12-28 |
2000-08-03 |
Fujisawa Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
|
US5891909A
(en)
|
1996-03-29 |
1999-04-06 |
3-Dimensional Pharmaceuticals, Inc. |
Amidinohydrazones as protease inhibitors
|
|
CA2258728C
(en)
|
1996-06-19 |
2011-09-27 |
Rhone Poulenc Rorer Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
|
DE69728688T2
(de)
|
1996-11-19 |
2004-08-19 |
Amgen Inc., Thousand Oaks |
Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
JP4327915B2
(ja)
|
1998-03-30 |
2009-09-09 |
株式会社デ・ウエスタン・セラピテクス研究所 |
スルフォンアミド誘導体
|
|
CA2344262A1
(en)
|
1998-09-18 |
2000-03-30 |
Basf Aktiengesellschaft |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6316503B1
(en)
*
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
|
AU6762400A
(en)
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
|
GEP20053477B
(en)
|
1999-08-13 |
2005-03-25 |
Biogen Inc |
Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them
|
|
EP1218336A2
(en)
|
1999-09-20 |
2002-07-03 |
Takeda Chemical Industries, Ltd. |
Melanin concentrating hormone antagonist
|
|
WO2002014361A2
(en)
|
2000-08-17 |
2002-02-21 |
Agensys, Inc. |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
|
|
TWI239942B
(en)
|
2001-06-11 |
2005-09-21 |
Dainippon Pharmaceutical Co |
N-arylphenylacetamide derivative and pharmaceutical composition containing the same
|
|
WO2003014075A2
(en)
|
2001-08-03 |
2003-02-20 |
Schering Corporation |
Novel gamma secretase inhibitors
|
|
KR100879693B1
(ko)
|
2001-08-17 |
2009-01-21 |
상꾜 아그로 가부시키가이샤 |
2-시클로프로필-6-메틸페놀
|
|
WO2003104428A2
(en)
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
|
DE10229777A1
(de)
|
2002-07-03 |
2004-01-29 |
Bayer Ag |
Indolin-Phenylsulfonamid-Derivate
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
US6894061B2
(en)
|
2002-12-04 |
2005-05-17 |
Wyeth |
Substituted dihydrophenanthridinesulfonamides
|
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
|
AU2003303231A1
(en)
|
2002-12-20 |
2004-07-14 |
Warner-Lambert Company Llc |
Benzoxazines and derivatives thereof as inhibitors of pi3ks
|
|
JP4601038B2
(ja)
|
2003-03-26 |
2010-12-22 |
第一三共株式会社 |
インドリルマレイミド類
|
|
US20080199486A1
(en)
|
2003-05-12 |
2008-08-21 |
Yair Argon |
Grp94-based compositions and methods of use thereof
|
|
KR20060070572A
(ko)
|
2003-09-18 |
2006-06-23 |
콘포마 세러퓨틱스 코포레이션 |
Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
|
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
|
US8067608B2
(en)
|
2003-09-29 |
2011-11-29 |
The Johns Hopkins University |
Hedgehog pathway antagonists
|
|
SE0302760D0
(sv)
|
2003-10-20 |
2003-10-20 |
Biovitrum Ab |
New compounds
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
ES2291984T3
(es)
|
2003-12-09 |
2008-03-01 |
F. Hoffmann-La Roche Ag |
Derivados de benzoxazina y su empleo.
|
|
US7569571B2
(en)
|
2003-12-23 |
2009-08-04 |
Novartis Ag |
Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators
|
|
WO2005084208A2
(en)
|
2004-02-27 |
2005-09-15 |
New York University |
A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
|
|
WO2005120558A2
(en)
|
2004-05-25 |
2005-12-22 |
University Of Connecticut Health Center |
Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
EP1771204A4
(en)
|
2004-07-01 |
2008-08-13 |
Univ New York |
COMPOSITIONS AND METHOD FOR MODULATING ROR-GAMMA-T
|
|
FR2874011B1
(fr)
|
2004-08-03 |
2007-06-15 |
Sanofi Synthelabo |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
US7304073B2
(en)
|
2004-08-20 |
2007-12-04 |
Wyeth |
Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
|
|
US20070010537A1
(en)
|
2004-08-20 |
2007-01-11 |
Kazumasa Hamamura |
Fused pyramidine derivative and use thereof
|
|
US7652043B2
(en)
|
2004-09-29 |
2010-01-26 |
The Johns Hopkins University |
WNT pathway antagonists
|
|
AU2005336093B2
(en)
|
2004-10-08 |
2011-02-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Adoptive immunotherapy with enhanced T lymphocyte survival
|
|
WO2006065495A2
(en)
|
2004-11-24 |
2006-06-22 |
Fred Hutchinson Cancer Research Center |
Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
|
|
AR051780A1
(es)
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
GB0514911D0
(en)
|
2005-07-20 |
2005-08-24 |
Univ Birmingham |
T cell memory assay
|
|
US8003624B2
(en)
|
2005-08-25 |
2011-08-23 |
Schering Corporation |
Functionally selective ALPHA2C adrenoreceptor agonists
|
|
BRPI0615307A2
(pt)
|
2005-08-25 |
2009-08-04 |
Schering Corp |
agonistas de adrenorreceptor alfa2c
|
|
JP2009509928A
(ja)
|
2005-09-01 |
2009-03-12 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
カリウムチャンネル開口剤としての新規ベンゾピラン誘導体
|
|
JP4843040B2
(ja)
|
2005-09-15 |
2011-12-21 |
エフ．ホフマン−ラ ロシュ アーゲー |
肝カルニチンパルミトイルトランスフェラーゼのインヒビターとして有用な新規ヘテロ二環式誘導体
|
|
FR2896798A1
(fr)
*
|
2006-01-27 |
2007-08-03 |
Sanofi Aventis Sa |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
JP4949413B2
(ja)
|
2006-02-13 |
2012-06-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
糖尿病の処置用のヘテロ二環式スルホンアミド誘導体
|
|
ES2439948T3
(es)
|
2006-02-17 |
2014-01-27 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
ES2579762T3
(es)
|
2006-03-01 |
2016-08-16 |
Janssen Pharmaceutica N.V. |
Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
|
|
EP2005177B1
(en)
|
2006-04-06 |
2013-07-10 |
Janssen R&D Ireland |
A homogeneous time resolved fluorescence based test method
|
|
CA2651072A1
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
|
AU2007255042A1
(en)
|
2006-06-01 |
2007-12-13 |
Wyeth |
1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
|
|
EP2046741B1
(en)
|
2006-07-03 |
2012-10-31 |
Proximagen Ltd. |
Indoles as 5-ht6 modulators
|
|
EP2038301A4
(en)
|
2006-07-12 |
2010-01-20 |
Oncotx Inc |
COMPOSITIONS AND METHODS OF TARGETING CANCER-SPECIFIC TRANSCRIPTION COMPLEXES
|
|
TWI315304B
(en)
|
2006-08-31 |
2009-10-01 |
Univ Taipei Medical |
Indoline-sulfonamides compounds
|
|
US8389739B1
(en)
|
2006-10-05 |
2013-03-05 |
Orphagen Pharmaceuticals |
Modulators of retinoid-related orphan receptor gamma
|
|
US20090275586A1
(en)
|
2006-10-06 |
2009-11-05 |
Kalypsys, Inc. |
Heterocyclic inhibitors of pde4
|
|
WO2008062740A1
(fr)
|
2006-11-20 |
2008-05-29 |
Japan Tobacco Inc. |
Composé azoté à anneaux fusionnés et son utilisation
|
|
US7799933B2
(en)
|
2006-12-21 |
2010-09-21 |
Hoffman-La Roche Inc. |
Sulfonamide derivatives
|
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
US8664359B2
(en)
|
2007-06-03 |
2014-03-04 |
Oncotx, Inc. |
Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets
|
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
|
US20110190280A1
(en)
|
2007-08-29 |
2011-08-04 |
George Adjabeng |
Thiazole And Oxazole Kinase Inhibitors
|
|
US7960376B2
(en)
|
2007-09-14 |
2011-06-14 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
|
EP2203746B1
(en)
|
2007-09-24 |
2013-03-06 |
Technion Research & Development Foundation Ltd. |
T cell subpopulations capable of treating cancer
|
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
|
US7960377B2
(en)
|
2008-03-28 |
2011-06-14 |
Cara Therapeutics, Inc. |
Substituted pyridoxazines
|
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
|
US8658635B2
(en)
|
2008-06-05 |
2014-02-25 |
Glaxosmithkline Intellectual Property Development Limited |
Benzpyrazol derivatives as inhibitors of PI3 kinases
|
|
ES2383246T3
(es)
|
2008-06-05 |
2012-06-19 |
Glaxo Group Limited |
4-amino-indazoles
|
|
US8329725B2
(en)
|
2008-06-09 |
2012-12-11 |
Sanofi |
Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
|
WO2009149819A1
(en)
|
2008-06-09 |
2009-12-17 |
Sanofi-Aventis |
Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
|
JPWO2009157196A1
(ja)
|
2008-06-25 |
2011-12-08 |
武田薬品工業株式会社 |
アミド化合物
|
|
WO2010017827A1
(en)
|
2008-08-14 |
2010-02-18 |
European Molecular Biology Laboratory |
6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
|
|
EP2321407A4
(en)
|
2008-09-11 |
2012-07-18 |
Univ Florida |
SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
|
|
NZ592008A
(en)
|
2008-10-02 |
2011-12-22 |
Taisho Pharmaceutical Co Ltd |
7-piperidinoalkyl-3,4-dihydroquinolone derivative
|
|
EP2181710A1
(en)
|
2008-10-28 |
2010-05-05 |
Phenex Pharmaceuticals AG |
Ligands for modulation of orphan receptor-gamma (NR1F3) activity
|
|
WO2010057101A2
(en)
|
2008-11-17 |
2010-05-20 |
Schering Corporation |
Compounds useful as hiv blockers
|
|
CN102281919A
(zh)
|
2008-11-19 |
2011-12-14 |
先灵公司 |
二酰基甘油酰基转移酶的抑制剂
|
|
EP2376502B1
(en)
|
2008-12-19 |
2015-06-17 |
GlaxoSmithKline LLC |
Thiazolopyridine sirtuin modulating compounds
|
|
TW201030007A
(en)
|
2009-02-06 |
2010-08-16 |
Gruenenthal Gmbh |
Substituted spiro-amides as b1r modulators
|
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
|
|
TW201102391A
(en)
|
2009-03-31 |
2011-01-16 |
Biogen Idec Inc |
Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
|
|
WO2010123139A1
(ja)
|
2009-04-24 |
2010-10-28 |
持田製薬株式会社 |
スルファモイル基を有するアリールカルボキサミド誘導体
|
|
WO2010125082A1
(en)
|
2009-04-30 |
2010-11-04 |
Glaxo Group Limited |
Oxazole substituted indazoles as pi3-kinase inhibitors
|
|
JP2013501057A
(ja)
|
2009-08-03 |
2013-01-10 |
ユニバーシティー・オブ・マイアミ |
制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
|
|
WO2011019634A2
(en)
|
2009-08-10 |
2011-02-17 |
Taipei Medical University |
Aryl substituted sulfonamide compounds and their use as anticancer agents
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
US9556201B2
(en)
|
2009-10-29 |
2017-01-31 |
Glaxosmithkline Llc |
Bicyclic pyridines and analogs as sirtuin modulators
|
|
EP2507226A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Novel compounds
|
|
US20120245171A1
(en)
|
2009-12-03 |
2012-09-27 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of pi3 kinases
|
|
EP2507231A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US20110142814A1
(en)
|
2009-12-16 |
2011-06-16 |
New York University |
Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
|
|
MX2012010115A
(es)
|
2010-03-01 |
2013-02-26 |
Gtx Inc |
Compuestos para el tratamiento de cancer.
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
WO2011115892A1
(en)
*
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
RS54286B1
(sr)
|
2010-09-08 |
2016-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
|
|
US9326987B2
(en)
|
2010-09-08 |
2016-05-03 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
|
WO2012037108A1
(en)
|
2010-09-13 |
2012-03-22 |
Glaxosmithkline Llc |
Aminoquinoline derivatives as antiviral agents
|
|
CN103491956A
(zh)
*
|
2010-09-13 |
2014-01-01 |
麦克罗拜奥提斯公司 |
病毒进入哺乳动物细胞的抑制剂
|
|
CA2816753A1
(en)
|
2010-11-08 |
2012-05-18 |
Lycera Corporation |
N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
US9629910B2
(en)
|
2011-03-22 |
2017-04-25 |
The Brigham And Women's Hospital, Inc. |
Use of Th9 cells and IL-9 for the treatment of melanoma
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
EP2511263A1
(en)
|
2011-04-14 |
2012-10-17 |
Phenex Pharmaceuticals AG |
Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
WO2012158784A2
(en)
|
2011-05-16 |
2012-11-22 |
Theodore Mark Kamenecka |
Modulators of the nuclear hormone receptor ror
|
|
BR112013033309B1
(pt)
|
2011-06-24 |
2022-07-05 |
Gri Bio, Inc |
Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
|
|
BR112014003704A2
(pt)
|
2011-09-19 |
2017-03-07 |
Eth Zuerich |
moduladores ror gama
|
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
NZ629283A
(en)
|
2012-03-16 |
2016-04-29 |
Covagen Ag |
Novel binding molecules with antitumoral activity
|
|
WO2013167136A1
(en)
|
2012-05-08 |
2013-11-14 |
Herlev Hospital |
Improving adoptive cell therapy with interferon gamma
|
|
AU2013259737A1
(en)
|
2012-05-08 |
2014-10-02 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
|
MX363350B
(es)
|
2012-05-08 |
2019-03-20 |
Merck Sharp & Dohme |
COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES.
|
|
JP6242868B2
(ja)
|
2012-05-08 |
2017-12-06 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
|
|
CA2874735A1
(en)
|
2012-05-25 |
2013-11-28 |
Health Diagnostic Laboratory, Inc. |
Rapid and high-throughput analysis of sterols/stanols or derivatives thereof
|
|
WO2014026327A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026328A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026329A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
WO2014028669A1
(en)
|
2012-08-15 |
2014-02-20 |
Biogen Idec Ma Inc. |
Novel compounds for modulation of ror-gamma activity
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
WO2014095757A1
(en)
*
|
2012-12-17 |
2014-06-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
|
|
WO2014201378A1
(en)
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
|
US9663502B2
(en)
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
|
WO2015095795A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
US9783511B2
(en)
|
2013-12-20 |
2017-10-10 |
Lycera Corporation |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
US9896441B2
(en)
|
2014-05-05 |
2018-02-20 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|